Lenvatinib Plus Pembrolizumab vs. Chemotherapy in Pretreated Patients With Advanced Endometrial Cancer: A Cost-Effectiveness Analysis

BACKGROUND: In the international, randomized, open-label, phase 3 study 309-KEYNOTE-775 trial, lenvatinib plus pembrolizumab (LP) showed improved progression-free survival (PFS) and overall survival (OS) compared with chemotherapy in pretreated patients with advanced endometrial cancer. This study a...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Mingyang, Chen, Yue, Yang, Yang, Li, Qiu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Public Health
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9127138/
https://www.ncbi.nlm.nih.gov/pubmed/35619813
http://dx.doi.org/10.3389/fpubh.2022.881034

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9127138/
https://www.ncbi.nlm.nih.gov/pubmed/35619813
http://dx.doi.org/10.3389/fpubh.2022.881034

Ejemplares similares